International Myeloma Foundation Endorses Texas Oral Drug Parity Bill HB 438

Share Article

Passage would represent a win for all cancer patients undergoing chemotherapy. Bill sent to governor for signing.

HB 438 passed in the State Senate on Tuesday and was sent to the Governor for signing. This bill will eliminate disparity in insurance coverage between oral and intravenous chemotherapy therapies, ensuring that all cancer patients in Texas have access to treatment. Please write to Governor Perry TODAY and ask him to sign HB 438.

Oral drug parity is one of the issues that the International Myeloma Foundation (IMF) Advocacy team has been working on in various states and at the federal level for some time. Assisting them are volunteers across the country: multiple myeloma patients, family members and friends. These advocates, by writing letters to their state legislatures, truly make a difference. The bill now before Governor Rick Perry will represent a tremendous victory for the myeloma community and all cancer patients in Texas.

Once a rare disease of the elderly, multiple myeloma represents 1% of all cancers but is the second most common form of blood cancer, and it is being diagnosed in growing numbers and in increasingly younger people. Myeloma affects an estimated 750,000 people worldwide, and each year approximately 20,000 new cases are diagnosed in the United States alone.

About the International Myeloma Foundation
Founded in 1990, the IMF is the oldest and largest myeloma organization in the world, reaching more than 195,000 members in 113 countries. Focusing on four key areas—research, education, support and advocacy, the IMF’s mission is to improve the quality of life of myeloma patients while working toward prevention and a cure. The research arm of the IMF, the International Myeloma Working Group (IMWG), comprised of 145 leading collaborative researchers, continues to lead the way in myeloma treatment and research. The IMF can be reached at (800) 453-CURE. The global website is myeloma.org.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

David Girard
International Myeloma Foundation
818 487-7455
Email >
Visit website